You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK, and GSK is not responsible for the content provided on that site.

Skip to main content

You are using an unsupported browser.

Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Timeout

For US HCPs

For US Healthcare Professionals

  • Indication
    • SEA
    • CRSwNP
    • EGPA
    • HES
  • Prescribing Info
    • Prescribing Information
    • Patient Information
  • Indication
    • SEA
    • CRSwNP
    • EGPA
    • HES
  • Prescribing Information
    • Prescribing Information
    • Patient Information
  • Patient Site
  • GSK MedInfo
  • Request a Rep

Menu

NUCALA (mepolizumab) 100 mg/mL injection logo

Search

  • HOME
  • PATIENT TYPES
  • EOSINOPHILS & MOA
  • EFFICACY
    • STUDY RESULTS
    • COMORBIDITY DATA
    • STUDY DESIGN
  • SAFETY
  • DOSING & ADMINISTRATION
    • AT-HOME ADMINISTRATION
    • IN-OFFICE ADMINISTRATION
  • PATIENT ACCESS & SUPPORT
  • PATIENT SITE
  • REQUEST A REP
  • GSKMEDINFO
Indication & Important Safety Info
Indication

NUCALA is indicated for the add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.

NUCALA is indicated for the add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.

NUCALA is indicated for the add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.

Important Safety Information

CONTRAINDICATIONS
NUCALA should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.

CONTRAINDICATIONS
NUCALA should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.

CONTRAINDICATIONS
NUCALA should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions (eg, anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred with NUCALA. These reactions generally occur within hours of administration but can have a delayed onset (ie, days). If a hypersensitivity reaction occurs, discontinue NUCALA.

Acute Asthma Symptoms or Deteriorating Disease
NUCALA should not be used to treat acute asthma symptoms, acute exacerbations, or acute bronchospasm.

Opportunistic Infections: Herpes Zoster
Herpes zoster infections have occurred in patients receiving NUCALA. Consider vaccination if medically appropriate.

Reduction of Corticosteroid Dosage
Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with NUCALA. Decreases in corticosteroid doses, if appropriate, should be gradual and under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection
Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. If patients become infected while receiving NUCALA and do not respond to anti-helminth treatment, discontinue NUCALA until infection resolves.

ADVERSE REACTIONS
In a clinical trial in patients with CRSwNP receiving NUCALA, the most common adverse reactions (≥5%) were oropharyngeal pain and arthralgia.

Systemic reactions, including hypersensitivity, also occurred. Manifestations included urticaria, erythema, and rash; 1 of the 3 reactions occurred on the day of dosing.

Injection site reactions occurred at a rate of 2% in patients receiving NUCALA vs <1% in patients receiving placebo.

USE IN SPECIFIC POPULATIONS
The data on pregnancy exposures are insufficient to inform on drug-associated risk. Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as the pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimesters.

Please see full Prescribing Information and Patient Information for NUCALA.

MPLWCNT210134 August 2021

To report SUSPECTED ADVERSE REACTIONS, contact GSK at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

  • GSK.com
  • Legal Notice
  • Privacy Notice
  • Interest-based Ads
  • Contact Us

Trademarks are owned by or licensed to the GSK group of companies.

This is my caption
Back to Top